Reaction

Pyoderma Gangrenosum reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,521 reports · 66 co-occurring drugs

As of the last recalculation, Pyoderma Gangrenosum appears in 3,521 FAERS reports alongside 66 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-FKJP (PRR 59.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Adalimumab-Fkjp	412	59.4	59.9
Adalimumab-Aaty	412	58.1	58.7
Adalimumab-Adaz	431	54.9	55.3
Infliximab-Dyyb	190	40.6	40.8
Daspone	53	32.6	32.8
Dapsone Gel, 5%	53	32.6	32.8
Dapsone	53	29.8	29.9
Infliximab	752	25.6	25.7
Adalimumab	1,037	11.9	11.9
Azathioprine	169	11.9	11.9
Vedolizumab	156	11.2	11.2
Ustekinumab	180	10.9	10.9
Minocycline	21	10.7	10.7
Azacitidine	53	10.7	10.7
Tofacitinib Citrate	23	10.4	10.4
Prednisolone	288	10.2	10.2
Prednisolone Oral	288	10.2	10.2
Prednisolone Oral Solution	288	10.2	10.2
Anakinra	28	10.0	10.1
Cyclosporine	171	9.5	9.5
Isotretinoin	72	8.8	8.8
Mesalamine	78	8.4	8.4
Azacitidine For	25	8.2	8.2
Imatinib	23	7.8	7.8
Colchicine	34	7.7	7.7
Canakinumab	14	7.7	7.7
Human Immunoglobulin G	25	7.2	7.2
Daptomycin	11	7.1	7.1
Hydrocortisone Sodium Succinate	11	6.9	6.9
Metronidazole	71	6.7	6.7
Loperamide Hcl	14	6.5	6.5
Clobetasol Propionate Ointment Usp, 0.05%	11	6.3	6.3
Sulfasalazine	82	6.3	6.3
Clobetasol Propionate	11	6.3	6.3
Bimekizumab	21	5.9	5.9
Loperamide Hydrochloride Oral	10	5.8	5.8
Prednisone	417	5.4	5.4
Secukinumab	133	5.0	5.0
Clindamycin	23	4.8	4.8
Methotrexate Sodium	360	4.8	4.8
Methotrexate	310	4.7	4.7
Mercaptopurine	13	4.4	4.4
Risankizumab-Rzaa	59	4.3	4.3
Mycophenilic Acid	15	4.3	4.3
Cefepime Hydrochloride	11	4.0	4.0
Upadacitinib	55	4.0	4.0
Tocilizumab	73	3.8	3.8
Tacrolimus Ointment 0.1%	74	3.6	3.6
Tacrolimus Extended-Release Capsules	74	3.6	3.6
Meropenem	19	3.5	3.5
Voclosporin	5	3.4	3.4
Baricitinib	5	3.1	3.1
Erlotinib	5	3.1	3.1
Golimumab	42	2.9	2.9
Lenvatinib	16	2.9	2.9
Erlotinib Hydrochloride	6	2.8	2.8
Ibrutinib	37	2.7	2.7
Ixekizumab	16	2.6	2.6
Sunitinib Malate	17	2.6	2.6
Ocrelizumab	25	2.4	2.4
Venetoclax	22	2.1	2.1
Pembrolizumab	36	2.0	2.0
Certolizumab Pegol	40	2.0	2.0
Guselkumab	10	1.7	1.7
Cabozantinib	13	1.6	1.6
Pegfilgrastim	21	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.